What this examination is about
This study compares two medicines used for chronic lymphocytic leukemia and small lymphocytic lymphoma – these are slow-growing forms of blood cancer. Both diseases are often treated for a long time with special medicines that prevent the growth of cancer cells. The two medicines in this study are called ibrutinib and acalabrutinib. Although both worked well against the cancer, they can sometimes cause side effects related to the heart and blood pressure. These side effects can lead to patients having to stop treatment. This study wanted to determine which of the two medicines is safer for the heart and blood pressure.
How it is investigated
Researchers collected data from 270 cancer patients who were treated in practice at 30 American cancer clinics between 2017 and 2023. From this group, 90 patients received acalabrutinib and 180 patients received ibrutinib. The researchers reviewed medical records and noted whether patients developed high blood pressure problems, developed heart conditions, or had to stop their treatment due to side effects. They also counted how often patients had to go to the hospital, how long they stayed there, and how many specialist consultations were needed.
What came out
After more than two years of follow-up, clear differences became apparent. Patients using acalabrutinib had significantly fewer high blood pressure problems than patients on ibrutinib. They also discontinued their treatment less often because they could no longer manage severe side effects. When patients with heart problems did need to go to the hospital, this was more often the case in the ibrutinib group. Patients on acalabrutinib also required fewer hospital admissions and had shorter stays. They also needed fewer consultations with cardiologists.
What this does not say
This study is based on medical records from practical situations and not a planned study design, which means that certain factors were not perfectly equally distributed between the two groups. The acalabrutinib user group was smaller (90 versus 180 patients). We do not know whether these results would be the same in other countries or hospitals. It is also unclear whether these differences persist in the long term (longer than two years). This study shows what doctors have observed in practice, but it does not answer the question of why one drug appears safer than the other.